Mechanical Circulatory Support in Infarct-Related Cardiogenic Shock, Anticoagulation Benefit in Device-Detected AFib, Semaglutide in HFpEF Patients
In this week’s View, Dr. Eagle looks at temporary mechanical circulatory support in infarct-related cardiogenic shock. He then explores the anticoagulation benefit in device-detected atrial fibrillation with or without vascular disease as reported in a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. Finally, Dr. Eagle discusses a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials that documented the effectiveness of semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Heart Failure and Cardiomyopathies, Anticoagulation Management and Atrial Fibrillation, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Acute Coronary Syndromes, Prevention, Vascular Medicine
Keywords: EaglesEyeView, Mechanical Circulatory Support, Myocardial Infarction, Shock, Cardiogenic, Anticoagulants, Atrial Fibrillation, Stroke, Vascular Diseases, GLP-1 Receptor, Heart Failure, Heart Failure, Preserved Ejection Fraction, Obesity
